{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:33:10Z","timestamp":1777321990339,"version":"3.51.4"},"reference-count":62,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, extramedullary hematopoiesis (particularly symptomatic splenomegaly), constitutional symptoms, progressive cytopenias, and, in a subset of patients, leukemic transformation. The advent of the JAK1\/2 inhibitor ruxolitinib has revolutionized the management of MF, substantially improving splenomegaly, symptom burden, and, in some settings, overall survival. However, a substantial percentage of patients fail to achieve sustained benefit, are intolerant, or become refractory; real-world and clinical trial data indicate that approximately half of treated patients discontinue ruxolitinib treatment within 3 years and up to approximately 75% within 5 years, with poor outcomes after discontinuation (median survival in several series is approximately 12\u201314 months). In recent years, several new small molecules that act beyond the JAK-STAT axis have emerged in clinical development. These include agents targeting telomerase (imetelstat), epigenetic regulation via BET inhibition (pelabresib\/CPI-0610), the MDM2-p53 axis (navtemadlin\/KRT-232), erythroid maturation and the bone marrow microenvironment (luspatercept), PI3K signaling (parsaclisib), and PIM inhibitors (nuvisertib). Early clinical data show promising results for symptom and splenic control in specific settings and, importantly, suggest potential disease-modifying activity (improvements in marrow fibrosis and molecular responses) for some compounds. This review summarizes the biological rationale, key clinical data (efficacy and safety), ongoing randomized trials, and remaining knowledge gaps for these non-JAK small molecules in MF and offers practical considerations for integrating them into contemporary treatment algorithms.<\/jats:p>","DOI":"10.3390\/cancers18091370","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:24:51Z","timestamp":1777317891000},"page":"1370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Path Forward in MF: Small Molecules in the Limelight"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"first","affiliation":[{"name":"Hematology, St. Eugenio Hospital, Tor Vergata University, ASL Roma2, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-6334","authenticated-orcid":false,"given":"Malgorzata Monika","family":"Trawinska","sequence":"additional","affiliation":[{"name":"Hematology, St. Eugenio Hospital, Tor Vergata University, ASL Roma2, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2624","authenticated-orcid":false,"given":"Simona","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Unit, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Checcoli","sequence":"additional","affiliation":[{"name":"Pharmacy, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4703-6280","authenticated-orcid":false,"given":"Martina","family":"Canichella","sequence":"additional","affiliation":[{"name":"Hematology, St. Eugenio Hospital, Tor Vergata University, ASL Roma2, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary Myelofibrosis: 2021 Update on Diagnosis, Risk-stratification and Management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) Consensus Report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in Patients with Primary or Secondary Myelofibrosis Who Are Candidates for Allogeneic Hematopoietic Cell Transplantation: A Position Paper on Behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.27270","article-title":"Risk Models in Myelofibrosis-the Past, Present, and Future","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Polverelli, N., Farina, M., D\u2019Adda, M., Damiani, E., Grazioli, L., Leoni, A., Malagola, M., Bernardi, S., and Russo, D. (2022). How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells, 11.","DOI":"10.3390\/cells11030553"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1182\/blood-2024-209545","article-title":"Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis","volume":"144","author":"Farina","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garuffo, L., Leoni, A., Gatta, R., and Bernardi, S. (2025). The Applications of Machine Learning in the Management of Patients Undergoing Stem Cell Transplantation: Are We Ready?. Cancers, 17.","DOI":"10.3390\/cancers17030395"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"Hemasphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis Biology and Contemporary Management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107719","DOI":"10.1016\/j.leukres.2025.107719","article-title":"Treatment Strategies and Survival after Ruxolitinib Discontinuation in Myelofibrosis Patients: The Italian RUX-MF Multicenter Study","volume":"154","author":"Palandri","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Farina, M., Bernardi, S., Polverelli, N., D\u2019Adda, M., Malagola, M., Bosio, K., Re, F., Almici, C., Dunbar, A., and Levine, R.L. (2021). Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells, 10.","DOI":"10.3390\/cells10102764"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/j.clml.2025.02.015","article-title":"Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis","volume":"25","author":"Palandri","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41375-022-01544-x","article-title":"Clinical and Molecular Correlates of JAK-Inhibitor Therapy Failure in Myelofibrosis: Long-Term Data from a Molecularly Annotated Cohort","volume":"36","author":"England","year":"2022","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal Evolution and Outcomes in Myelofibrosis after Ruxolitinib Discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.35244","article-title":"Myelofibrosis: Current Unmet Needs, Emerging Treatments, and Future Perspectives","volume":"130","author":"Harrison","year":"2024","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41375-026-02871-z","article-title":"Sequential Treatment with Ruxolitinib and Imetelstat Effectively Depletes Myelofibrosis Hematopoietic Stem and Progenitor Cells","volume":"40","author":"Wang","year":"2026","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK Inhibitor: IMpactMF Phase III Study Design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1080\/10428194.2025.2563739","article-title":"Outcomes with Imetelstat in Myelofibrosis: A Systematic Review and Meta-Analysis","volume":"66","author":"Shahzad","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs. Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase 3 Trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.2217\/fon-2022-0901","article-title":"BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed\/Refractory Myelofibrosis","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13543784.2023.2294324","article-title":"Treatment of Anemia in Myelofibrosis: Focusing on Novel Therapeutic Options","volume":"33","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s00277-024-05847-0","article-title":"Treatment of Myelofibrosis with Refractory Anemia with Luspatercept: A Multicenter Chinese Study","volume":"103","author":"Wang","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2022.2093192","article-title":"Targeting the PI3K Pathway in Myeloproliferative Neoplasms","volume":"22","author":"Gerds","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/bloodadvances.2023011620","article-title":"Phase 2 Study of Add-on Parsaclisib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results","volume":"8","author":"Yacoub","year":"2024","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/1078-0432.CCR-22-3192","article-title":"PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis","volume":"29","author":"Moyo","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1182\/blood-2024-200268","article-title":"A Phase 1\/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the Treatment of Anemia in Myelodysplastic Syndromes and Primary Myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14728214.2021.2015320","article-title":"Emerging Drugs for the Treatment of Myelofibrosis: Phase II & III Clinical Trials","volume":"26","author":"Tremblay","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hatzimichael, E., Timotheatou, D., Koumpis, E., Benetatos, L., and Makis, A. (2022). Luspatercept: A New Tool for the Treatment of Anemia Related to \u03b2-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis. Diseases, 10.","DOI":"10.3390\/diseases10040085"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1182\/blood-2023-178536","article-title":"Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study","volume":"142","author":"Gerds","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2023-174453","article-title":"Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study","volume":"142","author":"Komrokji","year":"2023","journal-title":"Blood"},{"key":"ref_36","unstructured":"(2025, December 21). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04717414."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S2152-2650(23)01234-X","article-title":"MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)","volume":"23","author":"Kiladjian","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2025-907","article-title":"Safety and Efficacy of Bromodomain and Extra-Terminal Protein Inhibitor INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study","volume":"146","author":"Vachhani","year":"2025","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","article-title":"Momelotinib vs. Ruxolitinib in Myelofibrosis Patient Subgroups by Baseline Hemoglobin Levels in the SIMPLIFY-1 Trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Chifotides, H.T., Giallongo, S., Giallongo, C., Tibullo, D., and Palumbo, G.A. (2024). ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. Cancers, 16.","DOI":"10.3390\/cancers16010154"},{"key":"ref_41","unstructured":"(2025, December 21). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04551066."},{"key":"ref_42","unstructured":"(2025, December 26). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04551053."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.27658","article-title":"Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives","volume":"100","author":"Loscocco","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-023-00696-6","article-title":"Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis","volume":"18","author":"Harrison","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2023.2300710","article-title":"Results from Phase 1 of the MANIFEST Clinical Trial to Evaluate the Safety and Tolerability of Pelabresib in Patients with Myeloid Malignancies","volume":"65","author":"Stein","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1182\/bloodadvances.2023010628","article-title":"Matching-Adjusted Indirect Comparison of the Pelabresib-Ruxolitinib Combination vs JAKi Monotherapy in Myelofibrosis","volume":"7","author":"Gupta","year":"2023","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-134262","article-title":"An Open-Label, Global, Multicenter, Phase 1b\/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood-2024-201642","article-title":"Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed\/Refractory Myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy in Combination with Ruxolitinib in Models of MPN","volume":"3","author":"Mazzacurati","year":"2019","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1158\/1078-0432.CCR-20-4898","article-title":"Therapeutic Efficacy of Combined JAK1\/2, Pan-PIM, and CDK4\/6 Inhibition in Myeloproliferative Neoplasms","volume":"27","author":"Rampal","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_52","unstructured":"(2026, January 10). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04176198."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Olschok, K., Altenburg, B., de Toledo, M.A.S., Maurer, A., Abels, A., Beier, F., Gezer, D., Isfort, S., Paeschke, K., and Br\u00fcmmendorf, T.H. (2023). The Telomerase Inhibitor Imetelstat Differentially Targets JAK2V617F versus CALR Mutant Myeloproliferative Neoplasm Cells and Inhibits JAK-STAT Signaling. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1277453"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Stuckey, R., Segura D\u00edaz, A., and G\u00f3mez-Casares, M.T. (2025). Myelofibrosis: Treatment Options After Ruxolitinib Failure. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32060339"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2022.12.014","article-title":"SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis","volume":"23","author":"Chifotides","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1182\/blood-2025-5535","article-title":"Transcriptomic Analysis of CD34+ Cells in Myelofibrosis Highlights Their Role in Extracellular Matrix Dysregulation and Marrow Fibrosis","volume":"146","author":"Bernardi","year":"2025","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clml.2023.05.002","article-title":"Phase 1\/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination with Standard-of-Care Agents in Patients with Advanced Hematologic Malignancies","volume":"23","author":"Patel","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12672-024-01252-1","article-title":"Momelotinib in Myelofibrosis and beyond: A Comprehensive Review of Therapeutic Insights in Hematologic Malignancies","volume":"15","author":"Dadkhah","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2025-1977","article-title":"Discovery of JAK2V617F Mutant Specific Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms","volume":"146","author":"Padyana","year":"2025","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100193","DOI":"10.1016\/j.bneo.2026.100193","article-title":"Mutant Calreticulin\u2013Directed Immunotherapies in Myeloproliferative Neoplasms","volume":"3","author":"Heaton","year":"2026","journal-title":"Blood Neoplasia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:38:22Z","timestamp":1777318702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091370"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091370","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]}}}